

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (CURRENTLY AMENDED) An isolated nucleotide sequence chosen from the group comprising SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 19, SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23, SEQ ID No. 24, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27 [[and]] or SEQ ID No. 28.

2. CANCELLED.

3. CANCELLED.

4. CANCELLED.

5. CANCELLED.

6. CANCELLED.

7. CANCELLED.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

8. (CURRENTLY AMENDED) A method for genotypically diagnosing cavernomas in an individual, ~~characterized in that~~ wherein the method comprises providing a biological sample ~~is taken~~ from said individual, ~~and in that~~ and detecting the presence of a mutation in **[[the]]** a *Krit1* gene ~~is detected by analyzing the nucleic acid sequence present in said sample, such a~~ wherein said mutation **[[being]]** is linked to the occurrence of cavernomas.

9. (CURRENTLY AMENDED) The diagnostic method as claimed in claim 8, ~~characterized in that~~ wherein the nucleic acid sequence is genomic DNA, cDNA or mRNA.

10. (CURRENTLY AMENDED) The diagnostic method as claimed in ~~either of claims~~ claim 8 **[[and 9]]**, ~~characterized in that~~ wherein said analysis detecting ~~is carried out by~~ comprises hybridization.

11. (CURRENTLY AMENDED) The diagnostic method as claimed in ~~one of claims~~ claim 8 **[[to 10]]**, ~~characterized in that~~ wherein said analysis detecting ~~is carried out by~~ comprises sequencing.

12. (CURRENTLY AMENDED) The diagnostic method as claimed in ~~either of claims~~ claim 8 **[[and 9]]**, ~~characterized in that~~ wherein said analysis detecting ~~is carried out by~~ comprises electrophoretic migration, and more particularly by SSCP or DGGE.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

13. (CURRENTLY AMENDED) The diagnostic method as claimed in either of claims claim 8 [[and 9]], characterized in that wherein said analysis detecting is carried out by comprises detecting methodology aimed at detecting the truncation of a protein.

14. (CURRENTLY AMENDED) The diagnostic method as claimed in one of claims claim 8 [[to 13]], characterized in that wherein all or part of the nucleic acid sequence corresponding to the *Krit1* gene is amplified prior to detecting the presence of a mutation.

15. (CURRENTLY AMENDED) The diagnostic method as claimed in claim 14, characterized in that wherein the amplification is carried out by PCR or PCR-like amplification.

16. (CURRENTLY AMENDED) The diagnostic method as claimed in claim 15, characterized in that wherein the primers for carrying out the amplification are from the sequences defined in claim 1, preferably in claim 5 is primed by a pair of nucleotide sequences according to claim 1.

17. CANCELLED.

18. CANCELLED.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

19. (CURRENTLY AMENDED) A vector for expression in a suitable host cell, ~~characterized in that it~~ wherein the vector comprises a sequence of the *Krit1* gene or a sequence derived from the *Krit1* gene.

20. (CURRENTLY AMENDED) The expression vector as claimed in claim 19, ~~characterized in that it~~ wherein the vector comprises [[the]] elements required for the overexpression of the sequence.

21. (CURRENTLY AMENDED) The vector as claimed in claim [[19 or]] 20, intended for use as claimed in either of claims 17 and 18 wherein the vector is a gene therapy vector.

22. (CURRENTLY AMENDED) The vector as claimed in ~~one of claims~~ ⁶ claim 19 to 21, characterized in that it , wherein the vector further comprises a sequence for tissue-specific targeting and/or expression.

23. (CURRENTLY AMENDED) A therapeutic composition, ~~characterized in that it comprises, as active principle, at least~~ comprising all or part of the normal or modified *Krit1* protein.

24. CANCELLED.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

25. (NEW) The diagnostic method as claimed in claim 16, wherein the pair of nucleotide sequences is

SEQ ID No. 1 and SEQ ID No. 2,
SEQ ID No. 3 and SEQ ID No. 4,
SEQ ID No. 5 and SEQ ID No. 6,
SEQ ID No. 7 and SEQ ID No. 8,
SEQ ID No. 9 and SEQ ID No. 10,
SEQ ID No. 11 and SEQ ID No. 12,
SEQ ID No. 13 and SEQ ID No. 14,
SEQ ID No. 15 and SEQ ID No. 16,
SEQ ID No. 17 and SEQ ID No. 18,
SEQ ID No. 19 and SEQ ID No. 20,
SEQ ID No. 21 and SEQ ID No. 22,
SEQ ID No. 23 and SEQ ID No. 24,
SEQ ID No. 25 and SEQ ID No. 26, or
SEQ ID No. 27 and SEQ ID No. 28.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com